HighGravityDataGilead Sciences — Aug 4, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000882095-26-000028
Showing in the filing
GAAP projected operating income (loss) (in millions)
“$(2,250) - $(1,850)”
Period
FY2026
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 20
Product sales (in millions) for FY2026
“$ 30,100 $ 30,400”
Product sales
“$ 30,100”
Product sales excluding Veklury (in millions) for FY2026
“$ 29,800 $ 30,100”
Product sales excluding Veklury
“$ 29,800”
Veklury (in millions) for FY2026
“~ $300”
Veklury
“~ $300”
Diluted loss per share for FY2026
“$ (3.75) $ (3.40)”
Diluted loss per share
“$ (3.75)”
Non-GAAP diluted loss per share for FY2026
“$ (0.65) $ (0.30)”
Non-GAAP diluted loss per share
“$ (0.65)”
Quarterly dividend declared for Q3 FY2026
“$0.82 per share”
Quarterly dividend of common stock for Q3 FY2026
“$0.82 per share”
GAAP projected product gross margin for FY2026
“~ 79.0%”
Non-GAAP projected product gross margin for FY2026
“~ 87.0%”
GAAP projected operating income (loss) (in m… for FY2026
“$(2,250) - $(1,850)”
Non-GAAP projected operating income (in mill… for FY2026
“$2,900 - $3,300”
GAAP projected effective tax rate excluding … for FY2026
“~21%”
GAAP projected effective tax rate for FY2026
“~ (80%) - (90%)”
Non-GAAP projected effective tax rate exclud… for FY2026
“~20%”
Non-GAAP projected effective tax rate for FY2026
“~ 140% - 115%”
Exhibit 99.1 · the passage around this item
… earlier in the release
RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE (1) (unaudited) (in millions, except percentages and per share amounts) Provided February 10, 2026 Updated May 7, 2026 Updated August 4, 2026 Projected product gross margin GAAP to non-GAAP reconciliation: GAAP projected product gross margin ~ 79.0% ~ 79.0% ~ 79.0% Acquisition-related expenses ~ 8.0% ~ 8.0% ~ 8.0% Non-GAAP projected product gross margin ~ 87.0% ~ 87.0% ~ 87.0% Projected operating income (loss) GAAP to non-GAAP reconciliation: GAAP projected operating income (loss) $11,400 - $11,900 $(1,000) - $(500) $(2,250) - $(1,850) Acquisition-related, IPR&D impairment, restructuring and other expenses ~ 2,400 ~ 3,400 ~ 5,150 Non-GAAP projected operating income $13,800 - $14,300 $2,400 - $2,900 $2,900 - $3,300 Projected effective tax rate GAAP to non-GAAP reconciliation: (2) GAAP projected effective tax rate ~ 21% ~ (150%) - (220%) ~ (80%) - (90%) Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments (~ 1%) NM NM Non-GAAP projected effective tax rate ~ 20% ~ 190% - 140% ~ 140% - 115% Projected diluted earnings (loss) per share GAAP to non-GAAP reconciliation: GAAP projected diluted earnings (loss) per share $6.75 - $7.15 $(3.25) - $(2.85) $(3.75) - $(3.40) Acquisition-related, IPR&D impairment, restructuring and other expenses, fair value adjustments of equity securities and discrete and related tax adjustments ~ 1.70 ~ 2.20 ~ 3.10 Non-GAAP projected diluted earnings (loss) per share $8.45 - $8.85 $(1.05) - $(0.65) $(0.65) - $(0.30) ________________________________ NM - Not Meaningful (1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been ex
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.